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INVESTIGATION
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Francis Spinale,§ Timothy Stearns,† Milena B. Furtado,† and Gary A. Churchill,†
*Yale University School of Medicine, New Haven, CT 06520, †The Jackson Laboratory, Bar Harbor, ME 04609,
‡Connecticut Children’s Medical Center, University of Connecticut School of Medicine, Hartford, CT 06106, and
§University of South Carolina School of Medicine, Columbia SC 29208
ORCID IDs: 0000-0003-1181-3544 (C.J.Z.); 0000-0001-9190-9284 (G.A.C.)
ABSTRACT Anthracyclines cause progressive cardiotoxicity whose ultimate severity is individual to the
patient. Genetic determinants contributing to this variation are difficult to study using current mouse models.
Our objective was to determine whether a spectrum of anthracycline induced cardiac disease can be elicited
across 10 Collaborative Cross mouse strains given the same dose of doxorubicin. Mice from ten distinct strains
were given 5 mg/kg of doxorubicin intravenously once weekly for 5 weeks (total 25 mg/kg). Mice were killed at
acute or chronic timepoints. Body weight was assessed weekly, followed by terminal complete blood count,
pathology and a panel of biomarkers. Linear models were fit to assess effects of treatment, sex, and sex-by-
treatment interactions for each timepoint. Impaired growth and cardiac pathology occurred across all
strains. Severity of these varied by strain and sex, with greater severity in males. Cardiac troponin I and
myosin light chain 3 demonstrated strain- and sex-specific elevations in the acute phase with subsequent
decline despite ongoing progression of cardiac disease. Acute phase cardiac troponin I levels predicted
the ultimate severity of cardiac pathology poorly, whereas myosin light chain 3 levels predicted the
extent of chronic cardiac injury in males. Strain- and sex-dependent renal toxicity was evident.
Regenerative anemia manifested during the acute period. We confirm that variable susceptibility to
doxorubicin-induced cardiotoxicity observed in humans can be modeled in a panel of CC strains. In
addition, we identified a potential predictive biomarker in males. CC strains provide reproducible
models to explore mechanisms contributing to individual susceptibility in humans.
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The chemotherapeutic use of anthracyclines is limited by their capacity
to induce dose-dependent cardiotoxicity (Gianni et al. 2008), leading to
development of heart failure and death(Gianni et al. 2008; Toro-Salazar
et al. 2015). Efficacy and toxicity of anthracycline agents is highly vari-
able in humans, reflecting the genetic diversity of patient populations as
well as gender differences (Franco et al. 2011; Lipshultz et al. 2015).
Multifactorial mechanisms including changes in cellular oxidative stress
and viability contribute to acute anthracycline-induced cardiotox-
icity (AIC) (De Angelis et al. 2010; Simu˚nek et al. 2009; Semsei et al.
2012). Maladaptive cardiac remodeling, comprising myocyte hyper-
trophy and extracellular matrix alterations (including loss of normal
fibrillar collagen architecture and interstitial fibrosis) are associated with
chronic induced toxicity and development of heart failure (Bernaba
et al. 2010; Toro-Salazar et al. 2013; Adamcova et al. 2010). Anthracy-
cline induced adverse cardiac remodeling is thought to be mediated
through inflammation and cytokine release in response to oxidative
stress (Bernaba et al. 2010).
Cardiac troponin elevation during chemotherapy is a useful tool in
risk stratification for future cardiac injury (Bertinchant et al. 2003;
Cardinale et al. 2004) however, this protein is released in serum only
Copyright © 2019 Zeiss et al.
doi: https://doi.org/10.1534/g3.119.400232
Manuscript received April 1, 2019; accepted for publication June 19, 2019;
published Early Online July 1, 2019.
This is an open-access article distributed under the terms of the Creative Commons
Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/),
which permits unrestricted use, distribution, and reproduction in any medium,
provided the original work is properly cited.
Supplemental material available at FigShare: https://doi.org/10.25387/g3.8284058.
1Corresponding author: Comparative Medicine, Yale University School of Medicine,
TAC N230, New Haven, CT 06510. E-mail: caroline.zeiss@yale.edu
Volume 9 | August 2019 | 2637
after cardiac tissue damage has occurred. The purpose of this study is to
develop a suite of mouse models that model variable susceptibility to
cardiotoxicity in human patients. These can be used to interrogate the
mechanisms of AIC, and to identify early predictive biomarkers and
risk alleles. Current approaches to preclinical testing using animal
models aim to minimize variability by limiting genetic diversity. This
can yield preclinical findings biased by genetic background and impede
subsequent translation to more complex human systems. Genetically
diverse mice, such as the Collaborative Cross (CC) better recapitulate
the range of phenotypes seen in the human population compared to a
single inbred strain (Harrison et al. 2014; Collaborative Cross Consor-
tium 2012). CC strains are recombinant inbredmice derived from eight
inbred founder strains (A/J, C57BL/6J, 129S1/SvImJ, NOD/ShiLtJ,
NZO/HlLtJ, CAST/EiJ, PWK/PhJ & WSB/EiJ) that encompass 90%
of the genetic diversity available in the laboratory mouse. CC strains
provide reproducible genetic backgrounds with fixed inbred genotypes.
Since each CC strain is inbred, each represents a reproducible model
with some degree of susceptibility to AIC. Using 10 strains of CCmice,
we identify distinct strain and sex-specific susceptibility to AIC. Addi-
tionally, we correlate the severity of strain-specific AIC with serum
biomarker levels and assess the capacity of these to predict the extent
of eventual cardiac injury.
METHODS
Experimental animals and doxorubicin dosing
We obtained CC mice from the Jackson Laboratory from each of
the following strains: CC001/UncJ, CC010/GeniUncJ, CC011/UncJ,
CC019/TauUncJ, CC032/GeniUncJ, CC037/TauUncJ, CC040/TauUncJ,
CC041/TauUncJ,CC042/GeniUncJ, andCC051/TauUncJ. Forbrevitywe
will drop the substrain designations below. Dose protocols based on a
previous juvenile model of doxorubicin-induced cardiac dysfunction
were applied(Zhu et al. 2008). 32 mice per CC strain equally split by
sex and treatment regimen (acute and chronic doxorubicin treatment
and control groups) were used. A total of 25 mg/kg of doxorubicin
(5 tail vein injections of 5 mg/kg in saline were given at 7-day
intervals beginning at 28 days (4 weeks) of age. Two time courses
for experimental endpoint were chosen; acute and chronic. Eight
dosed mice per CC strain (4 males and 4 females) were killed one
week after the final doxorubicin injection to study acute cardio-
toxicity (6 weeks; acute phase). A second cohort of dosed mice
(4 males and 4 females) per CC strain were killed 6 weeks after
the final doxorubicin injection to study the chronic effects of the
drug (12 weeks; chronic phase). An equivalent number of control
mice (8 males and 8 females) per CC line were subjected to the
same experimental regimen, with the exception that they received
weekly injections of saline instead of doxorubicin (control). The
animals were observed daily for general health, and weighed
weekly throughout the course of the study. Animals were group
housed by sex in ventilated cages with corn-cob bedding. They
were placed on a 12:12 light:dark cycle, and provided regular ad
libidum chow and water. The Jackson Laboratory (Mount Desert
Island, ME) is an AAALAC accredited facility. All procedures were
performed in accordance with NIH regulations and approved by
the Jackson laboratory Institutional Animal Care and Use Com-
mittee under the number 15009. (Figure1)
Serum biomarker measurement
Blood sampleswereobtained for eachanimal at the endof 6weeks (acute
phase) or 12 weeks (chronic phase). Following euthanasia by carbon
dioxide asphyxiation, animals were exsanguinated by cardiac puncture
and blood collected in serum separator tubes for cardiac troponin
I (cTNI), skeletal troponin I (sTNI), myosin light chain 3 (MYL3)
and fatty acid binding protein 3 (FABP1) measurement using the
Muscle Injury Panel kit from Meso Scale Discovery (MSD; Rockville,
MD) following the manufacturer’s instructions. Average values for
the lower limit of detection for each assay as provided by the man-
ufacturer (https://www.mesoscale.com/en/products/muscle-injury-
panel-3-mouse-kit-k15186c/) are as follows: cTNI (0.0088 ng/ml),
FABP3 (0.3 ng/ml), MYL3 (0.048 ng/ml) and sTNI (0.085 ng/ml).
50ml of undiluted serum was used per reaction.
Complete blood count
An aliquot of blood was collected in Microtainer tubes coated with
EDTA (BD Biosciences, Franklin Lakes, NJ) for measurement of white
blood cell count (WBC), platelets, red blood cell count (RBC), hemo-
globin (Hb), hematocrit (HCT), mean corpuscular volume (MCV),
mean corpuscular hemoglobin (MCH) and mean corpuscular hemo-
globin concentration (MCHC). Whole blood measurements were per-
formed by the JAXClinical Assessment Service using the SiemensAdvia
120 hematology analyzer.
Gross necropsy and organ weights
Following euthanasia by carbon dioxide asphyxiation, the pluck was
removed, lungs intratracheally inflated with 10% neutral buffered
formalin, and the intact heart and lungs, aswell as reproductive tract,
liver, spleen and right kidney immersed in 10% neutral buffered
formalin (NBF) for 7-10 days. Organ weights (kidneys, liver, spleen)
were recorded as a percentage of total body weight.
Figure 1 Study design. 10 CC strains were selected. 32 mice per line
equally split by sex and treatment regimen (acute and recovery
doxorubicin treatment and control groups) were used. A total of
25 mg/kg of DOX (5 tail injections of 5 mg/kg in saline were given at
7-day intervals beginning at 28 days of age. Two time courses for
experimental duration were chosen. Eight dosed mice per CC line
(4 males and 4 females) were killed one week after the final doxorubicin
injection to study acute cardiotoxicity (acute phase). A second cohort of
dosed mice (4 males and 4 females) per CC strain were killed 6 weeks
after the final DOX injection to study the chronic effects of the drug
(chronic or recovery phase). This regimen was duplicated for a similar
cohort of control mice, who received weekly injections of saline. Mice
were weighed weekly. At either 6 or 12 weeks, acute and chronic
cohorts were killed, blood taken for serum biomarkers and complete
blood count (CBC), and tissue collected for pathology.
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Histopathology and immunohistochemistry
All tissuesunderwent routineparaffinprocessing followedby sectioning
at 5 mm and staining with Hematoxylin and Eosin (H&E; Yale Mouse
Research Pathology Core in the Section of Comparative Medicine, Yale
School of Medicine; http:/mrp.yale.edu). Hearts were sectioned longi-
tudinally to allow visualization of all four chambers. Using hematoxylin
and eosin (HE) stained sections, two sections of each heart were scored
semi-quantitatively for severity of cardiac injury (adapted from pre-
viously published methods (Desai et al. 2013; Desai et al. 2014; Reagan
et al. 2013) using three histologic variables. These were cytoplasmic
vacuolation, (Desai et al. 2014; Ferrans 1978) infiltration by mononu-
clear cells, (Desai et al. 2013) and interstitial fibrosis with myofiber
disorganization/atrophy (Ferrans 1978). Each criterion was scored on
a 4-point scale with 0 representing normal histologic appearance and
3 representing themost severe score (see S1 Table 1 for scoring system).
The scale was applied to each of 5 anatomical regions (left and right
atrium, interventricular septum, left and right ventricular free wall).
Uncommon histologic findings (mineralization, atrial thrombosis,
perivascular lymphocytes) were recorded by region as absent (0) or
present (1). The scores for each anatomical region were summed to
obtain a total cardiac score for each animal. Two longitudinal renal
sections from the right kidney were examined for each animal. Semi-
quantitative renal scoring was achieved by recording the approximate
percentage per section occupied by a series of glomerular and tubular
changes (S1 Table 1). Scores for each change were summed to obtain a
composite score for each kidney. A similar approach was used to score
pulmonary pathology. Criteria for semi-quantitative scoring of cardiac,
renal and pulmonary lesions are given in S1 Table 1. Gonadal, liver and
splenic pathology was recorded as present or absent, and described
qualitatively only. The pathologist was blinded as to treatment status
and strain of each mouse.
The relationship between myofiber degeneration/atrophy, intersti-
tial fibrosis and mononuclear cell infiltration was explored by supple-
menting H&E staining with reticulin staining to reveal changes in the
reticulin (Type III collagen) framework surrounding myofibers, Sir-
ius Red staining (for Type II collagen), and immunohistochemical
detection of macrophages (Iba-1; ab107159, 1:100, Abcam, Cambridge,
MA), myofibroblasts (alpha smooth muscle actin; SMA; ms113,1:1500,
Neomarkers, Fremont, CA), matrix metalloproteinase 2 (MMP-2;
1:100, 6E3F8, ab86607, Abcam, Cambridge, MA) and cleaved cas-
pase-3 (NB100-56113, 1: 1000, Novus Biologicals, Littleton, CO).
Statistical analysis
i) Body/organ weight: After batch normalization (Johnson et al. 2007),
we fit linear models to assess effects of treatment, sex, and sex-by-
treatment interaction for each timepoint (acute or chronic). Linear
models utilize the statistical method of linear regression to describe
the relationship between a dependent variable y (or response) as a
function of one or more independent variables Xi (or predictors).
Generalized linear mixed models include random effects that allow
modeling of correlated data that may be non-normally distributed.
This allows evaluation of the extent to which interaction between
independent variables affects the response. Data were transformed
as log(x+c), where the offset constant c was determined by visual
inspection of quantile plots to best approximate a normal distribu-
tion (Berry 1987). ii) Cardiac and renal scoring: Log(y + 10) trans-
formed raw data were used to fit a linear model that examined the
main effects of treatment, sex and timepoint (acute or chronic) with
two additional terms examining interactions of treatment with sex
and timepoint. iii) Serum biomarkers: Following batch normalization,
various transformations were used for cTNI [log(x + 0.001)], FABP3
[log(x)], MYL3 [log(x + 0.01)], and for sTNI [log(x + 0.1)]. Results were
reported as estimates (standard error) with Benjamini-Hochberg ad-
justed p-values. For each strain, a mixed-effects model with sex, treat-
ment, timepoint, sex by treatment and treatment by timepoint as
fixed effects and mouse as a random effect was used. This approach
was chosen as both acute and chronic measurements for some mice
were available, and only acute measurements for others within a
strain. To assess whether cTNI and MYL3 levels in the acute phase
predict the ultimate extent of cardiac injury (as quantified by cardiac
scores in the chronic timepoint), a linear model was applied to each
sex. Only mice that survived to the chronic timepoint with provided
cTNI or MYL3 measurements during the acute timepoint were in-
cluded (65 data points, 29 female and 36 males).
Data access and analysis
Supplemental files include S1 Table 1 (semi-quantitative histologic
scoring systems), renal pathology and severity scoring (S2 Table 2
and S1 Figure 1), biomarker data for cardiac troponin I, myosin light
chain 3, fatty acid binding protein 3 and serum troponin 1 (S3 Table 3,
S4 Table), extra-cardiac histopathology (S2 Figure 2) and hematologic
data (S3Figure 3). Supplementalmaterial available at FigShare: https://
doi.org/10.25387/g3.8284058.
RESULTS
Animal survival and changes in body weight
One control animal in the chronic cardiotoxicity group died prior to
completion of the study period. 7 animals across both sexes in the acute
treatment group died prematurely (strains CC001, CC 032, CC 042,
CC 024, CC 040). 17 animals in the chronic cardiotoxicity group died.
Deaths occurred across both sexes and in 7/10 strains (CC 001, CC 032,
CC 042, CC 024, CC 019, CC 010, CC 040), but were clearly over-
represented in one strain (CC040). CC040was a very susceptible strain,
withmost animalsdyingby the endof12weeks.A similar trendwas seen
for females of CC 019 and CC 042. Consistent with previously reported
data across animal species (Bertinchant et al. 2003; Desai et al. 2013;
Manno et al. 2016), doxororubicin -treated animals demonstrated
impaired growth over time compared to age matched vehicle treated
controls. This varied by strain and sex. Significant differences in indi-
vidual organ weights were noted in four instances (data not shown),
but no pattern was identified. (Figure 2)
Cardiac disease scoring
Scores for each anatomical regionwere summed toobtain a total cardiac
score for eachanimal. Lesions occurred in all compartments of the heart,
with higher scores indicating increasing severity across all anatomical
locations. Cardiac severity scores were higher in the majority of doxo-
rubicin-treated animals (Figure 3). These treatment effects reached
statistical significance in 6 strains (CC011, CC019, CC032, CC040,
CC042, CC051) (Table 1). In CC011, significance was driven by con-
sistently low scores in controls, as scores in treated animals were
relatively low at both time points. Thus we did not consider CC011
to be a strain with a strong adverse treatment effect.More severe cardiac
pathology was noted in most chronically treated animals, timepoint
(acute vs. chronic) was statistically significant for strain CC032, and
the interaction of treatment with timepoint was significant in four
strains (CC001, CC019, CC041, CC042). Susceptibility to doxorubi-
cin-induced cardiac injury varied by sex with greater injury occurring
in either males (CC010, CC037, CC041) or in females (CC001). No
strain was immune to some degree of cardiac damage, however varying
strain susceptibility to cardiac toxicity induced by doxorubicin could be
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discerned. Overall, three strains appeared relatively resistant to chronic
cardiac injury (CC011, CC037 and CC051), with all remaining strains
experiencing chronic injury, most severe in CC019 and CC032, CC041
and CC042 (note that most animals in CC040 had died by the chronic
stage, and are absent from the analysis). These animals had high renal
scores in the acute stage and are likely to have died from combined
cardiac and renal toxicity – pathology was not available. Rare vehicle
treated animals experienced myofiber vacuolation, disintegration and
focal fibrosis - these clustered by strain and were considered a mani-
festation of mild strain-specific cardiac pathology unrelated to doxo-
rubicin exposure (CC001, CC019, CC041).
Qualitative cardiac pathology
Acutely intoxicated hearts experienced subtle changes characterized
primarily by intracytoplasmic myofiber vacuolation typical of doxoru-
bicin toxicity (Figure 4). Additional changes included disintegration
of individual myofibers, aggregation of small numbers of macrophages
(Figure 5), or regions of subtle disorganization characterized by sub-
jective individual myofiber atrophy. These changes were randomly
scattered through the myocardium, but noted most commonly in ven-
tricles and interventricular septum. Atrial pathology was similar in
nature, and could be locally more severe in individual animals, with
atrial thrombosis (Figure 4), myofiber loss and fibrosis, macrophage
and myofibroblast infiltration (Figure 5). Pathology in chronically
intoxicated hearts was generally more extensive. The prevailing
pattern was one of myofiber disorganization, marked variation in
myofiber diameter and fine chicken-wire like interstitial fibrosis
(Figure 4, Figure 6). Intracytoplasmic vacuolation did not prevail,
but was still evident in some animals. Rarely, focal regions of myofiber
loss and frank replacement fibrosis were noted (Figure 5). This pat-
tern was more common in atria and was accompanied by scattered
macrophage infiltration and myofibroblast proliferation consistent
with fibroplasia (Figure 5)(Zhao et al. 2015). In chronically intoxi-
cated animals, histologic abnormalities were often very severe in atria,
Figure 2 Body weight. Means and
standard error at each weekly time
point are shown for each strain, with
a vertical gray line delineating acute
(6 weeks) and chronic (12 week) time
points. Females are shown on the
top panel and males beneath. Doxo-
rubicin-treated animals (red) all dem-
onstrate impaired growth over time
compared to age matched vehicle
treated controls (blue). Significant
p values (,0.05) for treatment effect
(black asterisk), or treatment sex in-
teraction (white asterisk) at acute or
chronic timepoints are shown (aster-
isks are placed on either side of the
vertical gray line to indicate signifi-
cance at either acute or chronic timepoints). CC 40 was a very susceptible strain, with all most animals dying by the end of 12 weeks. A similar trend
is seen for females of CC 19 and CC 42.
Figure 3 Overview of cardiac scores
across all 10 CC lines. Means and
standard error at each weekly time
point are shown for each strain, with
a vertical gray line delineating acute
(A; 6 weeks) and chronic (C; 12 week)
time points. Females are shown on
the top panel and males beneath.
The majority of doxorubicin-treated
animals (red) demonstrate cardiac
injury (increased scores) over time
compared to age matched vehicle
treated controls (blue). Strains with
p values ,0.05 for treatment effect,
treatmentsex, and treatmenttimepoint
interactions are indicated with black,
gray and white asterisks respectively (lo-
cated above each strain name). Red
and blue rectangles indicate those
strains in which both sexes exhibit
marked doxorubicin susceptibility or
resistance respectively. Strain 40 is
very susceptible, with most doxorubi-
cin-treated animals dying before the
end of the study.
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where they were often accompanied by lymphoplasmacytic and his-
tiocytic inflammation, myofiber loss, focal scarring and atrial throm-
bosis. As noted in other doxorubicin toxicity studies (Kobayashi et al.
2016; Toya et al. 2014), macrophage and myofibroblast infiltration
were far less prominent in areas of diffusemyofiber disorganization and
fine fibrosis (Figure 6) - in these areas, SMA expression was increased in
myofiber cytoplasm, consistent with pathological re-expression fetal
markers (Szibor et al. 2014). Rare individual myofibers expressed
Mmp2, most commonly in the chronic phase (Figure 5). Myofibers
immunopositive for cleaved caspase-3 were uncommon, even during
the acute phase (Figure 5).
Extracardiac pathology
Renal toxicitywasnoted inseveral strains.Renal severityscores tendedto
be higher in the majority of doxorubicin-treated animals (S1 Figure 1),
with significance treatment effects seen in 3 strains (CC011, CC019,
CC040) (S2 Table 2). All of these strains also experienced significant
cardiotoxicity. Susceptibility to doxorubicin-induced renal injury varied
by sex with greater injury occurring in males (CC001, CC037, CC040,
CC042). Of these strains, a similar male susceptibility to cardiotoxicity
was noted in CC037. Qualitatively, the least severe and most common
renal changes were characterized by increased glomerular cellularity.
More severe changes involved glomeruli (increased mesangial matrix,
segmental tuft atrophy or diffuse glomerulosclerosis), tubules (focal
tubular basophilia, tubular loss, atrophy and dilation) and interstitium
(fibrosis andmononuclear inflammation; S2 Figure 2). Splenic changes
ranged from expansion of red pulp with marked extramedullary hem-
atopoeisis to complete red pulp collapse in both acute and recovery
treatment groups (S2 Figure 2). White pulp remained intact, consistent
with relatively unchanged lymphocyte counts.
Doxorubicin treatment in males was invariably associated with
severe testicular degeneration. Untreated males of some strains expe-
rienced mild testicular degeneration of a similar nature, consistent with
previously reported strain-dependent testicular pathology (CC001,
CC032, CC051, CC010)(Shorter et al. 2017).
Pulmonarypathologyconsistentwithheart failurewasevident inonly
one strain (CC040) in recovery phase animals with very high cardiac
scores. Striking pulmonary vascular pathology (intense perivascular
n Table 1 Statistical analysis of semi-quantitative cardiac scoring
Strain Treatment Sex Time Sex X Trt Trt X timepoint
CC 01 0.076 (0.041) 20.034 (0.034) 20.045 (0.034) 20.019 (0.048) 0.14 (0.048) 
CC 10 0.067 (0.031) 20.031 (0.026) 0.052 (0.027) 0.099 (0.036)  0.021 (0.037)
CC 11 0.072 (0.02)  20.039 (0.016) 0.009 (0.016) 0.024 (0.023) 0.021 (0.023)
CC 19 0.138 (0.025)  20.028 (0.02) 0.034 (0.02) 0.015 (0.028) 0.075 (0.029) 
CC 32 0.172 (0.025)  20.029 (0.021) 0.112 (0.021)  20.038 (0.029) 20.01 (0.029)
CC 37 20.003 (0.028) 20.022 (0.023) 0.036 (0.023) 0.114 (0.031)  0.038 (0.031)
CC 40 0.136 (0.04)  0.03 (0.033) 20.01 (0.033) 0.033 (0.052) 0.153 (0.061)
CC 41 0.006 (0.031) 20.069 (0.03) 0.019 (0.03) 0.178 (0.039)  0.097 (0.039) 
CC 42 0.094 (0.032)  20.007 (0.024) 20.018 (0.024) 0.009 (0.036) 0.131 (0.036) 
CC 51 0.103 (0.033)  20.022 (0.027) 0.015 (0.027) 0.024 (0.037) 20.028 (0.037)
Linear model examining main effects (sex, treatment;Trt and time) and two additional treatment interactions (with sex and time). All values are given as estimates
(standard error). Benjamini-Hochberg adjusted p-values are indicated as asterisks.
P , 0.05.
P , 0.01.
P , 0.001.
CC040†: all but two animals in the chronic group died prematurely.
Figure 4 Cardiac histopathology in animals 6 weeks
(acute) and 12 weeks (chronic) after initiating doxorubi-
cin (Dox) treatment (25mg/kg total cumulative dose,
acute). Intracytoplasmic vacuolation typical of doxoru-
bicin toxicity (black arrows, A and inset), accompanied
by rare myofiber atrophy (white arrow, A) prevailed in
acutely intoxicated mice. In the chronic phase (B),
pathology was dominated by areas of disorganization
with marked variation in myofiber diameter, myofiber
vacuolation in some animals (black arrows), and fine
chicken-wire like fibrosis (white arrows, C and inset, Sirius
Red). Atrial pathology was accompanied in some cases
by atrial thrombosis (C). Atrial lesions were characterized
by myofiber vacuolation (white arrows, D), myofiber
atrophy/loss, and lymphohistiocytic inflammation (black
arrows, D). Atrial lesions (illustrated in an acute phase
animal in C) were more severe in the chronic phase.
Hematoxylin and eosin (A, D); Sirius Red staining (inset,
B). Bar = 50mm (A, B, inset B, D); 20mm (inset A);
200 mm (C).
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mixed inflammation with marked endothelial proliferation) was
noted in untreated mice of one strain (CC032) consistent with
strain–associated pathology unrelated to doxorubicin treatment.
Serum biomarkers
Alteration in serum cardiac troponin I (cTNI), myosin light chain
3 (MYL3), fatty acid binding protein 3 and serum troponin 1 in acute
and chronic phases were evaluated (S3 Table 3). Only cTNI (pg/ml) and
MYL3 (pg/ml) exhibited significant treatment effects across multiple
strains (Figure 7 and S4 Table 4). Both cTNI and MYL3 tended to
decrease between acute and chronic phases, in contrast to cardiac scores
which increased over time. These data indicate that serum levels of
these biomarkers are highest during acute cardiac injury, and decline
during the chronic phase, despite ongoing or worsening of cardiac
injury. The exception to this was strain CC 37, in which cTNI and
MYL3 levels increased over time. cTNI exhibited a significant treat-
ment effect in almost all strains, compared to a similar finding in 5/10
strains forMYL3, indicating that cTNI is themore sensitive indicator of
acute cardiac injury. We employed a linear model based test to assess
whether troponin levels in the acute phase predict the ultimate extent
of cardiac injury (as quantified by cardiac scores in the chronic
timepoint). We evaluated each sex separately to allow for potential
sex-specific differences. The significance for cTNI was quite low
(P = 0.42 and P = 0.30 for females and males, respectively) indicating
that cTNI values in the acute phase do not reliably predict the
ultimate extent of cardiac injury. When MYL3 is combined with
cTNI, the predictive power remained poor for both biomarkers in
females (P = 0.14 and P = 0.13 for cTNI and MYL3, respectively).
However in males, MYL3 appeared to be predictive for extent of
ultimate cardiac injury in the chronic phase (P = 0.15 and P = 0.94
for cTNI and MYL3, respectively).
Hematologic change
While doxorubicin did not greatly affect white blood cell counts, it had
a strong effect on red blood cell counts (RBC). The most consistent
hematologic changewas anemia thatmanifestedduring the acute period
(S3Figure 3).Anemiawas regenerative andhad recovered in the chronic
phase. RBCdecreased at the acute timepoint in almost all strains, except
CC051. Most strains recovered by the chronic time point, but some
strains (CC001, CC011, CC042) still had decreased RBC. Anemia was
accompaniedby increasedredbloodcelldistributionwidth (RDW) inall
strains at the acute time point, indicative of a regenerative response, and
consistent with extramedullary hematopoeisis noted histologically.
Most strains had recovered by the chronic time point, except for
CC032 and CC042. Platelets increased at the acute time point across
gender (CC011, CC040), or sex-specifically (CC001, CC019, CC032,
CC042). Most strains had recovered by the chronic time point. Doxo-
rubicin did not cause myelosuppression at either the acute (orange) or
chronic (blue) time points, and white blood cell (WBC) counts were
altered in varying patterns. Many strains (CC010, CC040, CC041)
Figure 5 Pathology in DOX treated acute and
recovery phase mice. Regions of myofiber loss
and frank replacement fibrosis were noted,
most commonly in atria (A, acute phase), and
rarely in ventricles (D, recovery phase). These
areas were accompanied by macrophage in-
filtration (B, E) and myofibroblast proliferation
(C) consistent with fibroplasia. Rare myofibers
were matrix metalloproteinase 2 (F, recovery
phase animal) or caspase-3 positive (G, acute
phase animal). Reticulin staining (A, D); Immu-
nohistochemistry: Iba 1(B, E; macrophages),
alpha SMA (C), MMP-2 (F) and cleaved cas-
pase -3 (G) Bar = 100mm (A-C); 50mm (D-F);
20mm (G).
Figure 6 Diffuse interstitial cardiac fi-
brosis in doxorubicin treated chronic
phase mice (left ventricle, A-C) com-
pared to vehicle treated control mice
(D-F) at a similar location. Reticulin
stains (A) revealed myofiber disorga-
nization, variation in myofiber diame-
ter and fine interstitial fibrosis. This was
accompanied by minimal macrophage
infiltration (B) and myofibroblast infil-
tration (C). Instead, SMA expression
was increased in myofiber cytoplasm
(C, inset). Reticulin staining (A, D);
Immunohistochemistry: Iba 1(B, E;
macrophages), alpha SMA (C, F).
Bar = 100mm (A-F); 20mm (inset, C).
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showed increased neutrophil counts at the acute time point. This
increase persisted at the chronic time point in some strains (CC010,
CC032, CC041).
DISCUSSION
Our approach in this study was to utilize cardiac scoring as the primary
outcome measure of cardiac injury, and to assess the capacity of bio-
marker scores to accurately predict the extent of cardiac injury. Ac-
companying changes in body weight, extracardiac pathology and
hematologic responses were secondary measures. We demonstrated
clear strain-dependent variation in cardiac (and renal) susceptibility to
doxorubicin induced toxicity. All strains experienced some degree of
cardiac injury –this invariably worsened over time in the chronic group
despite cessation of doxorubicin treatment by the end of week 6. Ex-
tremes of clear high (CC019, CC032 and CC040) and low (CC011 and
CC051) susceptibility across both sexes were identified in five strains. In
remaining strains, sex-dependent variations in susceptibility were pre-
sent. Consistent with previous reports(Jenkins et al. 2016), males were
more severely affected in most strains (CC010, CC019, CC041, CC042,
CC051) with females being more severely affected in only one strain
(CC001).
All anatomical regions of the heart were histologically affected –
lesions were typically scattered and quite rare in the acute phase of the
disease. Myofiber vacuolation characteristic of anthracycline toxicity
dominated acute cardiac histopathology, however, subtle myofiber dis-
organization and atrophy presaging later architectural distortion could
already be appreciated at this stage(Ferrans 1978). Cleaved caspase-3
positive myofibers were present in the acute phase, however these
were rare (0-5/section), indicating that extensive activation of terminal
apoptotic pathways was minimal, or alternatively, was short-lived, or
accompanied by necrotic forms of cell death (Zhang et al. 2016). In
chronic phase animals, two patterns of cardiac fibrosis were identified.
By far the most common was fine chicken-wire like interstitial fibrosis
(containing Sirius red positive Type 1 collagen) accompanied by per-
vasive myofiber atrophy and disorganization (most easily appreciable
using reticulin stains). Significant infiltration of macrophages (Iba-1)
and myofibroblasts (alpha-SMA) was not seen in these areas. Addi-
tionally, myofiber cytoplasm in fibrotic regions was strongly alpha-
SMA immunoreactive, indicating regression to a fetal phenotype
(Szibor et al. 2014), and raising the possibility that myofibers them-
selves contribute to pathologic extracellular matrix remodeling
through an aberrant transcriptional program (Bowers et al. 2010).
This notion is underscored by expression of Mmp-2 in myofibers,
thus implicating these in collagen remodeling. Interstitial and peri-
vascular deposition of collagen is characteristic of late stages of
cardiotoxicity and has been identified in subjects with AIC under-
going cardiac transplantation (Bernaba et al. 2010). A second pat-
tern of fibrosis characterized by focal marked myofiber loss,
replacement fibrosis (discrete scarring) and dense infiltration by
macrophages and myofibroblasts was evident. This was rare in ven-
tricular wall and much more common in atria. Severity of atrial
lesions was marked in chronic phase animals, and quite commonly
associated with lymphocytic inflammation and atrial thrombosis.
The latter is a previously noted lesion in murine (but not human)
doxorubicin toxicity(Fujihira et al. 1993).
cTNI is considered a myocardium-specific biomarker, whereas
MYL3 is present in both cardiac and skeletal muscle (Tonomura
et al. 2012). Regardless, both were generally elevated in treated acute
phase animals, and declined over time in chronic phase mice of all
strains except one (CC 037). These results suggest that myofibers are
injured by direct cardiotoxicity during periods of doxorubicin admin-
istration, but that different mechanisms contribute to adverse cardiac
Figure 7 Overview of cTNI and MYL3
levels across all 10 CC strains. Means
and standard error at each weekly
time point are shown for each strain,
with a vertical gray line delineating
acute (A; 6 weeks) and chronic (C;
12 week) time points. Females are
shown on the top panel and males
beneath. The majority of doxorubicin-
treated animals (red) demonstrate car-
diac injury (increased scores) over time
compared to age matched vehicle
treated controls (blue). Strains with
p values ,0.05 for treatment effect
are indicated with black asterisks.
Additional significant treatmentsex,
and treatmenttimepoint interactions
are shown in Supplementary Tables 3
and 4.
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remodeling with development of progressive microscopic fibrosis dur-
ing the chronic phase. Previous studies have demonstrated that AIC is
mediated in part by an effect on the collagen matrix with loss of extra-
cellular matrix and increase in fibrosis(Bernaba et al. 2010; Caulfield
and Bittner 1988; Toro-Salazar et al. 2013). Activation of matrix
metalloproteases (MMPs) and decreased levels of tissue inhibitors of
MMPs (TIMPs)(Kong et al. 2014) and inflammatorymediators play an
important role in LV remodeling. Myocyte hypertrophy (Spinale and
Zile 2013; Spinale 2002; Yokoyama et al. 1997), myosin heavy-chain
switch(Kubota et al. 1997), cardiac myocyte apoptosis (Krown et al.
1996) and extracellular matrix alterations with early loss of fibrillar
collagen followed by late microscopic fibrosis, contribute to adverse
cardiac remodeling ultimately leading to heart failure (Liew and Dzau
2004; Kong et al. 2014). In our pediatric early AIC cohort, we have
identified biomarker signatures in inflammatory, structural and cell
growth/viability pathways (Toro-Salazar et al. 2018). cTNI and
MYL3 exhibited significant treatment effects across 9 and 5 strains
respectively, suggesting that cTNI was the more sensitive indicator of
acute injury. In agreement with previous reports (Cardinale et al. 2004;
Bertinchant et al. 2003; Reagan et al. 2013), cTNI elevation in the acute
phase was not predictive of the eventual extent of cardiac injury as
assessed by cardiac score in either sex (Armenian et al. 2014;
Moazeni et al. 2017). MYL3 was similarly non-predictive in females,
however in males, MYL3 levels in the acute phase were correlated
with the extent of eventual cardiac injury, implicating a sex-specific
use for this biomarker. The latter finding should be interpreted with
caution –MYL3 is not cardiac-specific, and in rodents, its clearance can
be influenced by renal toxicity(Tonomura et al. 2012).
Both carbon dioxide euthanasia and cardiac puncture could con-
ceivably alter troponin levels in our cohort (Marquardt et al. 2018;
Everds 2017), however the of cardiac troponins to accurately predict
the extent of chronic cardiac injury remains an imperfect science. cTNI
is utilized in clinical practice (Horacek et al. 2008; Jones et al. 2017;
Simões et al. 2018; Ma et al. 2019). Cardiac troponin T has been used to
monitor anthracycline induced injury in clinical patients (Blaes et al.
2015; Bisoc et al. 2019), although its elevation following anthracycline
treatment is not invariable (Horacek et al. 2008; Lipshultz et al. 2004).
Both cTNI and cTNT are more reliable indicators of injury immedi-
ately following anthracycline exposure (Simões R et al., 2018). Assess-
ing the capacity of cTNT to predict the extent of chronic cardiac injury
would be a useful addition in subsequent studies using murine model
systems(Jenkins et al. 2016). Future studies in susceptible and resistant
CC strains will help define regulatory molecular pathways related to
AIC predictors in these genetic variants.
Marked renal toxicity was evident in some strains. Lesions recapit-
ulated previously described pathology centered on glomeruli (Yasuda
et al. 2010) with eventual extension to tubular and interstitial compo-
nents. In general, renal toxicity was less prevalent than cardiotoxicity.
In contrast to cardiac pathology, overall worsening of renal pathology
over time was not nearly asmarked.While some strains developed both
cardiac and renal injury across both sexes (CC019, CC040), others
exhibited relatively greater renal toxicity (CC051) indicating that some
genetic determinants of these two organ responses are shared, whereas
others are independently inherited. Like cardiotoxicity, susceptibility to
renal toxicity varied across strain, sex and timepoint. Renal toxicity is
well-described in rodents (Lee and Harris 2011) and pigs (Manno et al.
2016), but is less common in humans (Bárdi et al. 2007). The potential
of this lesion to affect biomarker clearance in mice (Tonomura et al.
2012), and thus confound translation of biomarker data from mice to
humans should not be underestimated. As in other species,(Manno
et al. 2016) severe testicular degeneration occurred in all treated males,
making this lesion the most consistent of all organ responses. Ovarian
atrophy was noted in some treated females, however this organ was not
available in sufficient sections to adequately assess strain susceptibility
of this response.
Doxorubicin treatment generally impeded the rate of weight gain
across strains, however the extent of this could not be clearly correlated
with the extent of cardiac injury. Because humans receiving doxorubicin
have the added variable of neoplasia, and because their weight is very
individual, body weight was not considered a translationally useful
biomarker. Bone marrow suppression is commonly a dose limiting
toxic effect during active doxorubicin treatment in humans (Panis et al.
2012), dogs (Ahaus et al. 2000) and pigs (Manno et al. 2016) . This
effect can manifest across erythroid, granulocytic and thrombocytic
lineages (Panis et al. 2012). We did not observe myelosuppression in
our mice. Consistent with previous reports in mice (Desai et al. 2013),
the most profound hematologic abnormality was anemia during the
acute phase. This was regenerative, and red cell counts had normalized
by the chronic phase. Marked splenic extramedullary hematopoeisis
followed by eventual red pup exhaustion was noted in many doxoru-
bicin treated mice, consistent with marked splenic hematopoeitic com-
pensation for bone marrow toxicity. In contrast to humans, in which
splenic extramedullary hematopoiesis is negligible, the adult murine
spleen (and to lesser extent the liver) are capable of profound extra-
medullary hematopoiesis when stimulated (Sonoda and Sasaki 2012).
In this study, a spectrumof cardiac pathology couldbe demonstrated
that exhibited a wide range across strains, but was consistent within
strain. Resistant and susceptible strains provide a powerful tool to
investigate pathophysiologic mechanisms driving cardiac injury, par-
ticularly those that follow acute intoxication to create chronic ongoing
injury. These strains are similarly useful in the search for early stage
biomarkers that can be used to predict the extent of chronic injury.
Because mice within each CC strain are virtually genetically identical
(over 90% homozygous), CC mice are most ideally suited to identifi-
cation of reproducible anthracycline sensitive and resistant phenotypes.
These can be used to interrogate cellular mechanisms of AIC, partic-
ularly those underlying progressive interstitial fibrosis, and to identify
early predictive biomarkers. For the identification of genetic determi-
nants contributing to AIC, genetically heterozygous mice generated
from the same 8 parental strains, i.e., the Diversity Outbred (DO)mice,
are better suited.
ACKNOWLEDGMENTS
The authors gratefully acknowledge the work of Gordon Terwilliger,
Michael Schadt and Arthur Nugent (Yale Research Pathology Core),
the JAX Scientific Cores of Clinical Assessment and In Vivo Services.
LITERATURE CITED
Adamcova, M., A. Potacova, O. Popelova, M. Sterba, Y. Mazurova et al.,
2010 Cardiac remodeling and MMPs on the model of chronic dauno-
rubicin-induced cardiomyopathy in rabbits. Physiol. Res. 59: 831–836.
Ahaus, E. A., C. G. Couto, and K. D. Valerius, 2000 Hematological toxicity
of doxorubicin-containing protocols in dogs with spontaneously occur-
ring malignant tumors. J. Am. Anim. Hosp. Assoc. 36: 422–426. https://
doi.org/10.5326/15473317-36-5-422
Armenian, S. H., S. K. Gelehrter, T. Vase, R. Venkatramani, W. Landier et al.,
2014 Screening for cardiac dysfunction in anthracycline-exposed
childhood cancer survivors. Clin. Cancer Res. 20: 6314–6323. https://
doi.org/10.1158/1078-0432.CCR-13-3490
Bárdi, E., I. Bobok, A. V. Oláh, J. Kappelmayer, and C. Kiss,
2007 Anthracycline antibiotics induce acute renal tubular toxicity in
children with cancer. Pathol. Oncol. Res. 13: 249–253. https://doi.org/
10.1007/BF02893506
2644 | C. J. Zeiss et al.
Bernaba, B. N., J. B. Chan, C. K. Lai, and M. C. Fishbein, 2010 Pathology
of late-onset anthracycline cardiomyopathy. Cardiovasc. Pathol. 19:
308–311. https://doi.org/10.1016/j.carpath.2009.07.004
Berry, D. A., 1987 Logarithmic transformations in ANOVA. Biometrics 43:
439–456. https://doi.org/10.2307/2531826
Bertinchant, J. P., A. Polge, J. M. Juan, M. C. Oliva-Lauraire, I. Giuliani et al.,
2003 Evaluation of cardiac troponin I and T levels as markers of
myocardial damage in doxorubicin-induced cardiomyopathy rats, and
their relationship with echocardiographic and histological findings. Clin.
Chim. Acta 329: 39–51. https://doi.org/10.1016/S0009-8981(03)00013-5
Bisoc, A., D. Ciurescu, M. Radoi, M. M. Tantu, L. Rogozea et al.,
2019 Elevations in High-Sensitive Cardiac Troponin T and N-Terminal
Prohormone Brain Natriuretic Peptide Levels in the Serum Can Predict
the Development of Anthracycline-Induced Cardiomyopathy. Am.
J. Ther. 1. https://doi.org/10.1097/MJT.0000000000000930
Blaes, A. H., A. Rehman, D. M. Vock, X. Luo, M. Menge et al., 2015 Utility
of high-sensitivity cardiac troponin T in patients receiving anthracycline
chemotherapy. Vasc. Health Risk Manag. 11: 591–594. https://doi.org/
10.2147/VHRM.S89842
Bowers, S. L., I. Banerjee, and T. A. Baudino, 2010 The extracellular matrix:
at the center of it all. J. Mol. Cell. Cardiol. 48: 474–482. https://doi.org/
10.1016/j.yjmcc.2009.08.024
Cardinale, D., M. T. Sandri, A. Colombo, N. Colombo, M. Boeri et al.,
2004 Prognostic value of troponin I in cardiac risk stratification of
cancer patients undergoing high-dose chemotherapy. Circulation 109:
2749–2754. https://doi.org/10.1161/01.CIR.0000130926.51766.CC
Caulfield, J. B., and V. Bittner, 1988 Cardiac matrix alterations induced by
adriamycin. Am. J. Pathol. 133: 298–305.
Collaborative Cross Consortium, 2012 The genome architecture of the
Collaborative Cross mouse genetic reference population. Genetics 190:
389–401. https://doi.org/10.1534/genetics.111.132639
De Angelis, A., E. Piegari, D. Cappetta, L. Marino, A. Filippelli et al.,
2010 Anthracycline cardiomyopathy is mediated by depletion of the
cardiac stem cell pool and is rescued by restoration of progenitor cell
function. Circulation 121: 276–292. https://doi.org/10.1161/
CIRCULATIONAHA.109.895771
Desai, V. G., E. H. Herman, C. L. Moland, W. S. Branham, S. M. Lewis et al.,
2013 Development of doxorubicin-induced chronic cardiotoxicity in
the B6C3F1 mouse model. Toxicol. Appl. Pharmacol. 266: 109–121.
https://doi.org/10.1016/j.taap.2012.10.025
Desai, V. G., J. C. Kwekel, V. Vijay, C. L. Moland, E. H. Herman et al.,
2014 Early biomarkers of doxorubicin-induced heart injury in a mouse
model. Toxicol. Appl. Pharmacol. 281: 221–229. https://doi.org/10.1016/
j.taap.2014.10.006
Everds, N. E., 2017 Deciphering Sources of Variability in Clinical
Pathology-It’s Not Just about the Numbers. Toxicol. Pathol. 45:
275–280. https://doi.org/10.1177/0192623316680783
Ferrans, V. J., 1978 Overview of cardiac pathology in relation to anthra-
cycline cardiotoxicity. Cancer Treat. Rep. 62: 955–961.
Franco, V. I., J. M. Henkel, T. L. Miller, and S. E. Lipshultz,
2011 Cardiovascular effects in childhood cancer survivors treated with
anthracyclines. Cardiol. Res. Pract. 2011: 134679. https://doi.org/10.4061/
2011/134679
Fujihira, S., T. Yamamoto, M. Matsumoto, K. Yoshizawa, Y. Oishi et al.,
1993 The high incidence of atrial thrombosis in mice given doxorubicin.
Toxicol. Pathol. 21: 362–368. https://doi.org/10.1177/019262339302100403
Gianni, L., E. H. Herman, S. E. Lipshultz, G. Minotti, N. Sarvazyan et al.,
2008 Anthracycline cardiotoxicity: from bench to bedside. J. Clin.
Oncol. 26: 3777–3784. https://doi.org/10.1200/JCO.2007.14.9401
Harrison, D. E., C. M. Astle, M. K. K. Niazi, S. Major, and G. L. Beamer,
2014 Genetically diverse mice are novel and valuable models of age-
associated susceptibility to Mycobacterium tuberculosis. Immun. Ageing
11: 24. https://doi.org/10.1186/s12979-014-0024-6
Horacek, J. M., R. Pudil, M. Tichy, L. Jebavy, A. Strasova et al.,
2008 Cardiac troponin I seems to be superior to cardiac troponin T in
the early detection of cardiac injury associated with anthracycline treat-
ment. Onkologie 31: 559–560. https://doi.org/10.1159/000151687
Jenkins, G. R., T. Lee, C. L. Moland, V. Vijay, E. H. Herman et al.,
2016 Sex-related differential susceptibility to doxorubicin-induced
cardiotoxicity in B6C3F1 mice. Toxicol. Appl. Pharmacol. 310: 159–174.
https://doi.org/10.1016/j.taap.2016.09.012
Johnson, W. E., C. Li, and A. Rabinovic, 2007 Adjusting batch effects in
microarray expression data using empirical Bayes methods. Biostatistics
8: 118–127. https://doi.org/10.1093/biostatistics/kxj037
Jones, M., P. O’Gorman, C. Kelly, N. Mahon, and M. C. Fitzgibbon,
2017 High-sensitive cardiac troponin-I facilitates timely detection of
subclinical anthracycline-mediated cardiac injury. Ann. Clin. Biochem.
54: 149–157. https://doi.org/10.1177/0004563216650464
Kobayashi, M., F. Usui, T. Karasawa, A. Kawashima, H. Kimura et al.,
2016 NLRP3 Deficiency Reduces Macrophage Interleukin-10
Production and Enhances the Susceptibility to Doxorubicin-induced
Cardiotoxicity. Sci. Rep. 6: 26489. https://doi.org/10.1038/srep26489
Kong, P., P. Christia, and N. G. Frangogiannis, 2014 The pathogenesis of
cardiac fibrosis. Cell. Mol. Life Sci. 71: 549–574. https://doi.org/10.1007/
s00018-013-1349-6
Krown, K. A., M. T. Page, C. Nguyen, D. Zechner, V. Gutierrez et al.,
1996 Tumor necrosis factor alpha-induced apoptosis in cardiac myo-
cytes. Involvement of the sphingolipid signaling cascade in cardiac cell
death. J. Clin. Invest. 98: 2854–2865. https://doi.org/10.1172/JCI119114
Kubota, T., C. F. McTiernan, C. S. Frye, S. E. Slawson, B. H. Lemster et al.,
1997 Dilated cardiomyopathy in transgenic mice with cardiac-specific
overexpression of tumor necrosis factor-alpha. Circ. Res. 81: 627–635.
https://doi.org/10.1161/01.RES.81.4.627
Lee, V. W., and D. C. Harris, 2011 Adriamycin nephropathy: a model of
focal segmental glomerulosclerosis. Nephrology (Carlton) 16: 30–38.
https://doi.org/10.1111/j.1440-1797.2010.01383.x
Liew, C. C., and V. J. Dzau, 2004 Molecular genetics and genomics of heart
failure. Nat. Rev. Genet. 5: 811–825. https://doi.org/10.1038/nrg1470
Lipshultz, S. E., V. I. Franco, T. L. Miller, S. D. Colan, and S. E. Sallan,
2015 Cardiovascular disease in adult survivors of childhood
cancer. Annu. Rev. Med. 66: 161–176. https://doi.org/10.1146/
annurev-med-070213-054849
Lipshultz, S. E., N. Rifai, V. M. Dalton, D. E. Levy, L. B. Silverman et al.,
2004 The effect of dexrazoxane on myocardial injury in doxorubicin-
treated children with acute lymphoblastic leukemia. N. Engl. J. Med. 351:
145–153. https://doi.org/10.1056/NEJMoa035153
Ma, Y., F. Bai, F. Qin, J. Li, N. Liu et al., 2019 Beta-blockers for the primary
prevention of anthracycline-induced cardiotoxicity: a meta-analysis of
randomized controlled trials. BMC Pharmacol. Toxicol. 20: 18. https://
doi.org/10.1186/s40360-019-0298-6
Manno, R. A., A. Grassetti, G. Oberto, A. Nyska, and Y. Ramot,
2016 The minipig as a new model for the evaluation of doxorubicin-
induced chronic toxicity. J. Appl. Toxicol. 36: 1060–1072. https://doi.org/
10.1002/jat.3266
Marquardt, N., M. Feja, H. Hunigen, J. Plendl, L. Menken et al.,
2018 Euthanasia of laboratory mice: Are isoflurane and sevoflurane real
alternatives to carbon dioxide? PLoS One 13: e0203793. https://doi.org/
10.1371/journal.pone.0203793
Moazeni, S., M. Cadeiras, E. H. Yang, M. C. Deng, and K. L. Nguyen,
2017 Anthracycline induced cardiotoxicity: biomarkers and “Omics”
technology in the era of patient specific care. Clin. Transl. Med. 6: 17.
https://doi.org/10.1186/s40169-017-0148-3
Panis, C., A. C. Herrera, V. J. Victorino, F. C. Campos, L. F. Freitas et al.,
2012 Oxidative stress and hematological profiles of advanced breast
cancer patients subjected to paclitaxel or doxorubicin chemotherapy.
Breast Cancer Res. Treat. 133: 89–97. https://doi.org/10.1007/
s10549-011-1693-x
Reagan, W. J., M. York, B. Berridge, E. Schultze, D. Walker et al.,
2013 Comparison of cardiac troponin I and T, including the evaluation
of an ultrasensitive assay, as indicators of doxorubicin-induced cardio-
toxicity. Toxicol. Pathol. 41: 1146–1158. https://doi.org/10.1177/
0192623313482056
Semsei, A. F., D. J. Erdelyi, I. Ungvari, E. Csagoly, M. Z. Hegyi et al.,
2012 ABCC1 polymorphisms in anthracycline-induced cardiotoxicity
Volume 9 August 2019 | Doxorubicin Cardiotoxicity in CC Mice | 2645
in childhood acute lymphoblastic leukaemia. Cell Biol. Int. 36: 79–86.
https://doi.org/10.1042/CBI20110264
Shorter, J. R., F. Odet, D. L. Aylor, W. Pan, C. Y. Kao et al., 2017 Male
Infertility Is Responsible for Nearly Half of the Extinction Observed in
the Mouse Collaborative Cross. Genetics 206: 557–572. https://doi.org/
10.1534/genetics.116.199596
Simões, R., L. M. Silva, A. Cruz, V. G. Fraga, A. de Paula Sabino et al.,
2018 Troponin as a cardiotoxicity marker in breast cancer patients re-
ceiving anthracycline-based chemotherapy: A narrative review. Biomed.
Pharmacother. 107: 989–996. https://doi.org/10.1016/j.biopha.2018.08.035
Simu˚nek, T., M. Sterba, O. Popelova, M. Adamcova, R. Hrdina et al.,
2009 Anthracycline-induced cardiotoxicity: overview of studies exam-
ining the roles of oxidative stress and free cellular iron. Pharmacol. Rep.
61: 154–171. https://doi.org/10.1016/S1734-1140(09)70018-0
Sonoda, Y., and K. Sasaki, 2012 Hepatic extramedullary hematopoiesis and
macrophages in the adult mouse: histometrical and immunohistochem-
ical studies. Cells Tissues Organs 196: 555–564. https://doi.org/10.1159/
000338336
Spinale, F. G., 2002 Matrix metalloproteinases: regulation and dysregula-
tion in the failing heart. Circ. Res. 90: 520–530. https://doi.org/10.1161/
01.RES.0000013290.12884.A3
Spinale, F. G., and M. R. Zile, 2013 Integrating the myocardial matrix into
heart failure recognition and management. Circ. Res. 113: 725–738.
https://doi.org/10.1161/CIRCRESAHA.113.300309
Szibor, M., J. Poling, H. Warnecke, T. Kubin, and T. Braun,
2014 Remodeling and dedifferentiation of adult cardiomyocytes during
disease and regeneration. Cell. Mol. Life Sci. 71: 1907–1916. https://
doi.org/10.1007/s00018-013-1535-6
Tonomura, Y., S. Matsushima, E. Kashiwagi, K. Fujisawa, S. Takagi et al.,
2012 Biomarker panel of cardiac and skeletal muscle troponins, fatty
acid binding protein 3 and myosin light chain 3 for the accurate diagnosis
of cardiotoxicity and musculoskeletal toxicity in rats. Toxicology 302:
179–189. https://doi.org/10.1016/j.tox.2012.07.012
Toro-Salazar, O. H., E. Gillan, J. Ferranti, A. Orsey, K. Rubin et al.,
2015 Effect of myocardial dysfunction in cardiac morbidity and all
cause mortality in childhood cancer subjects treated with anthracycline
therapy. Cardiooncology 1: 1–9.
Toro-Salazar, O. H., E. Gillan, M. O’Loughlin, G. S. Burke, J. Ferranti et al.,
2013 Occult Cardiotoxicity in Childhood Cancer Survivors Exposed to
Anthracycline Therapy. Circ Cardiovasc Imaging 6: 873–880. https://
doi.org/10.1161/CIRCIMAGING.113.000798
Toro-Salazar, O. H., J. H. Lee, K. N. Zellars, P. E. Perreault, K. C. Mason et al.,
2018 Use of integrated imaging and serum biomarker profiles to
identify subclinical dysfunction in pediatric cancer patients treated with
anthracyclines. Cardiooncology 4: 4. https://doi.org/10.1186/
s40959-018-0030-5
Toya, T., D. Hakuno, Y. Shiraishi, T. Kujiraoka, and T. Adachi,
2014 Arginase inhibition augments nitric oxide production and
facilitates left ventricular systolic function in doxorubicin-induced
cardiomyopathy in mice. Physiol. Rep. 2: e12130. https://doi.org/
10.14814/phy2.12130
Yasuda, K., H. C. Park, B. Ratliff, F. Addabbo, A. K. Hatzopoulos et al.,
2010 Adriamycin nephropathy: a failure of endothelial progenitor cell-
induced repair. Am. J. Pathol. 176: 1685–1695. https://doi.org/10.2353/
ajpath.2010.091071
Yokoyama, T., M. Nakano, J. L. Bednarczyk, B. W. McIntyre, M. Entman
et al., 1997 Tumor necrosis factor-alpha provokes a hypertrophic
growth response in adult cardiac myocytes. Circulation 95: 1247–1252.
https://doi.org/10.1161/01.CIR.95.5.1247
Zhang, T., Y. Zhang, M. Cui, L. Jin, Y. Wang et al., 2016 CaMKII is a RIP3
substrate mediating ischemia- and oxidative stress-induced myocardial
necroptosis. Nat. Med. 22: 175–182. https://doi.org/10.1038/nm.4017
Zhao, W., T. Zhao, Y. Chen, F. Zhao, Q. Gu et al., 2015 A Murine
Hypertrophic Cardiomyopathy Model: The DBA/2J Strain. PLoS One
10: e0133132. https://doi.org/10.1371/journal.pone.0133132
Zhu, W., W. Shou, R. M. Payne, R. Caldwell, and L. J. Field, 2008 A mouse
model for juvenile doxorubicin-induced cardiac dysfunction. Pediatr. Res.
64: 488–494. https://doi.org/10.1203/PDR.0b013e318184d732
Communicating editor: B. Andrews
2646 | C. J. Zeiss et al.
